Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients

AIDS

Volumn 27, Issue 8, 2013, Pages 1283-1293

  Zhang, Zheng ^a   Fu, Junliang ^a   Xu, Xiangsheng ^a   Wang, Siyu ^a   Xu, Ruonan ^a   Zhao, Min ^b   Nie, Weimin ^b   Wang, Xicheng ^c   Zhang, Jiyuan ^a   Li, Taisheng ^d   Su, Lishan ^e   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

^b Department of Infectious Diseases ^*  (China)

^c AIDS Care Center (YNACC)   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; HIV 1; Immune reconstitution; Mesenchymal stem cells; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL PARAMETERS; IN VIVO STUDY; INFLAMMATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; OPEN STUDY; PATIENT MONITOR; PATIENT SAFETY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSFUSION; UMBILICAL CORD;

ADOLESCENT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879105636     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835fab77     Document Type: Article

References (40)

1. Hammer SM, Squires KE, Hughes M.D., Grimes JM, Demeter LM, Currier JS, et al A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
2. Mocroft A, Vella S, Benfield T.L., Chiesi A., Miller V, Gargalianos P, et al Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Vo TT, Ledergerber B, Keiser O., Hirschel B, Furrer H, Battegay M., et al. Durability and outcome of initial antiretro-viral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685-1694.
4. Zhang F, Dou Z, Yu L., Xu J, Jiao JH, Wang N, et al The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008; 47:825-833.
5. Kelley CF, Kitchen CM, Hunt P.W., Rodriguez B., Hecht FM, Kitahata M, et al Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term anti-retroviral treatment. Clin Infect Dis 2009; 48:787-794.
6. Baker JV, Peng G, Rapkin J., Abrams DI, Silverberg MJ, MacArthur RD, et al CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
7. Smit C, Geskus R, Walker S., Sabin C, Coutinho R, Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749.
8. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299.
9. Li T, Wu N, Dai Y., Qiu Z, Han Y, Xie J., et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis 2011; 53:944-951.
10. Hunt PW, Martin JN, Sinclair E, Bredt B., Hagos E, Lampiris H, et al T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
11. Kuller LH, Tracy R, Belloso W., De Wit S, Drummond F, Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
12. Appay V. Sauce D Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
13. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
14. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
15. Levy Y, Lacabaratz C, Weiss L., Viard JP, Goujard C, Lelievre JD, et al Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
16. Levy Y, Sereti I, Tambussi G., Routy JP, Lelievre JD, Delfraissy JF, et al Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300.
17. Murray SM, Down CM, Boulware D.R., Stauffer WM, Cavert WP, Schacker TW, et al Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010; 84:12082-12086.
18. Piconi S, Parisotto S, Rizzardini G., Passerini S, Terzi R, Argenteri B., et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non-responders. Blood 2011; 118:3263-3272.
19. Paton NI, Goodall RL, Dunn D.T., Franzen S., Collaco-Moraes Y, Gazzard BG, et al Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308:353-361.
20. Uccelli A, Moretta L. Pistoia V Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726-736.
21. Le Blanc K., Frassoni F, Ball L., Locatelli F, Roelofs H, Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
22. Zhang Z, Lin H, Shi M., Xu R, Fu J, Lv J., et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroen-terol Hepatol 2012; 27 (SUPPL. 2):112-120.
23. Bai F, Bellistri GM, Tincati C, Savoldi A., Pandolfo A, Bini T, et al Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. AIDS 2010; 24:2590-2593.
24. Zhang SY, Zhang Z, Fu J.L., Kang FB, Xu XS, Nie WM, et al Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. Eur J Immunol 2009; 39:1425-1434.
25. Kaufmann DE. Walker BD Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS 2008; 3:362-367.
26. Zhang Z, Xu X, Lu J., Zhang S, Gu L, Fu J., et al. B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J Infect Dis 2011; 203:1668-1678.
27. Jiang W, Lederman MM, Hunt P, Sieg S.F., Haley K., Rodriguez B, et al Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
28. Xing S, Fu J, Zhang Z., Gao Y, Jiao Y, Kang F., et al. Increased turnover of FoxP3high regulatory T cells is associated with hyperactivation and disease progression of chronic HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54:455-462.
29. Kinter AL, Hennessey M, Bell A., Kern S, Lin Y, Daucher M., et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004; 200:331-343.
30. Sun L, Akiyama K, Zhang H., Yamaza T, Hou Y, Zhao S., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27:1421-1432.
31. Brenchley JM, Price DA, Schacker T.W., Asher TE, Silvestri G, Rao S, et al Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
32. Dyavar Shetty R., Velu V, Titanji K., Bosinger SE, Freeman GJ, Silvestri G, et al PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122:1712-1716.
33. Akiyama K, Chen C, Wang D.D., Xu X., Qu C, Yamaza T, et al Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10:544-555.
34. Douek DC, Picker LJ Koup RA T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
35. Kimmig S, Przybylski GK, Schmidt C.A., Laurisch K., Mowes B, Radbruch A, et al Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 2002; 195:789-794.
36. Muraro PA, Douek DC, Packer A, Chung K., Guenaga FJ, Cassiani-Ingoni R, et al Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201:805-816.
37. Tanchot C, Le Campion A, Martin B, Leaument S., Dautigny N. Lucas B Conversion of naive T cells to a memory-like pheno-type in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J Immunol 2002; 168:5042-5046.
38. Day CL, Kaufmann DE, Kiepiela P, Brown J.A., Moodley ES, Reddy S, et al PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
39. Trautmann L, Janbazian L, Chomont N., Said EA, Gimmig S, Bessette B, et al Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
40. Zhang JY, Zhang Z, Wang X., Fu JL, Yao J, Jiao Y, et al PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109:4671-4678.